Marc A. Pfeffer

发表

Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve

M. A. Sellers, M. Newman, M. Stafford-Smith, 2010, Quality and Safety in Health Care.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

James E. Tcheng, Christopher J. White, Norman L. Stockbridge, 2018, Circulation.

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

E. Braunwald, K. A. Hill, Daniel J. Rader, 2004, The New England journal of medicine.

Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

S. Solomon, M. Pfeffer, R. Califf, 2006, American heart journal.

Challenges in conducting clinical trials in nephrology Conduct Clinical Trials in Nephrology

M. Landray, V. Perkovic, C. Baigent, 2017 .

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF

Akshay S. Desai, S. Solomon, M. Pfeffer, 2021, Journal of the American Heart Association.

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.

M. Pfeffer, S. Yusuf, J. McMurray, 2000, American heart journal.

Buspirone pharmacokinetics in patients with cirrhosis.

H. Poulsen, P. Garred, K. Dalhoff, 1987, British journal of clinical pharmacology.

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

S. de Denus, Jiankang Liu, B. Claggett, 2024, International journal of cardiology.

Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.

P. Jhund, Li Shen, John J.V. McMurray, 2024, JAMA.

Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT)

M. Pfeffer, R. Califf, J. McMurray, 2005, Circulation.

Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.

M. Vaduganathan, A. Shah, M. Gori, 2024, European journal of heart failure.